Drug Details
| General Information of the Drug (ID: DR4869) | ||||
|---|---|---|---|---|
| Name |
Endostar
|
|||
| Synonyms |
Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn
Click to Show/Hide
|
|||
| Molecular Type |
Protein
|
|||
| Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Approved | [1] | |
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Ginsenoside Rg3 | Panax ginseng | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BECN1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | JNK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MMP-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFB | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFC | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | MCF-7 cells were inoculated under right mammary gland of female C57 mice. | |||||
| Experimental
Result(s) |
Endostar combined with ginsenoside Rg3 has stronger inhibiting effect on breast cancer tumor growth in tumor-bearing mice than single drug, and it can inhibit angiogenesis and cell invasion, and enhance cell autophagy. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Beta-catenin (CTNNB1) | Molecule Info | [1] | |
| KEGG Pathway | Rap1 signaling pathway | Click to Show/Hide | ||
| 2 | Wnt signaling pathway | |||
| 3 | Hippo signaling pathway | |||
| 4 | Focal adhesion | |||
| 5 | Adherens junction | |||
| 6 | Tight junction | |||
| 7 | Signaling pathways regulating pluripotency of stem cells | |||
| 8 | Leukocyte transendothelial migration | |||
| 9 | Melanogenesis | |||
| 10 | Thyroid hormone signaling pathway | |||
| 11 | Bacterial invasion of epithelial cells | |||
| 12 | Pathogenic Escherichia coli infection | |||
| 13 | HTLV-I infection | |||
| 14 | Pathways in cancer | |||
| 15 | Proteoglycans in cancer | |||
| 16 | Colorectal cancer | |||
| 17 | Endometrial cancer | |||
| 18 | Prostate cancer | |||
| 19 | Thyroid cancer | |||
| 20 | Basal cell carcinoma | |||
| 21 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | |||
| NetPath Pathway | IL2 Signaling Pathway | Click to Show/Hide | ||
| Panther Pathway | Alzheimer disease-presenilin pathway | Click to Show/Hide | ||
| 2 | Angiogenesis | |||
| 3 | Cadherin signaling pathway | |||
| 4 | Wnt signaling pathway | |||
| 5 | p53 pathway feedback loops 2 | |||
| 6 | CCKR signaling map ST | |||
| Pathway Interaction Database | Degradation of beta catenin | Click to Show/Hide | ||
| 2 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
| 3 | Coregulation of Androgen receptor activity | |||
| 4 | Arf6 trafficking events | |||
| 5 | Presenilin action in Notch and Wnt signaling | |||
| 6 | Integrin-linked kinase signaling | |||
| 7 | Nectin adhesion pathway | |||
| 8 | CDC42 signaling events | |||
| 9 | Canonical Wnt signaling pathway | |||
| 10 | FoxO family signaling | |||
| 11 | E-cadherin signaling events | |||
| 12 | Posttranslational regulation of adherens junction stability and dissassembly | |||
| 13 | E-cadherin signaling in the nascent adherens junction | |||
| 14 | AP-1 transcription factor network | |||
| 15 | E-cadherin signaling in keratinocytes | |||
| 16 | Regulation of nuclear beta catenin signaling and target gene transcription | |||
| 17 | Stabilization and expansion of the E-cadherin adherens junction | |||
| 18 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
| 19 | N-cadherin signaling events | |||
| 20 | RAC1 signaling pathway | |||
| 21 | TGF-beta receptor signaling | |||
| Reactome | TCF dependent signaling in response to WNT | Click to Show/Hide | ||
| 2 | Formation of the beta-catenin:TCF transactivating complex | |||
| 3 | LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | |||
| 4 | CDO in myogenesis | |||
| 5 | Deactivation of the beta-catenin transactivating complex | |||
| 6 | Ca2+ pathway | |||
| 7 | Binding of TCF/LEF:CTNNB1 to target gene promoters | |||
| 8 | Disassembly of the destruction complex and recruitment of AXIN to the membrane | |||
| 9 | S33 mutants of beta-catenin aren't phosphorylated | |||
| 10 | S37 mutants of beta-catenin aren't phosphorylated | |||
| 11 | S45 mutants of beta-catenin aren't phosphorylated | |||
| 12 | T41 mutants of beta-catenin aren't phosphorylated | |||
| 13 | RHO GTPases activate IQGAPs | |||
| WikiPathways | DNA Damage Response (only ATM dependent) | Click to Show/Hide | ||
| 2 | SIDS Susceptibility Pathways | |||
| 3 | TGF Beta Signaling Pathway | |||
| 4 | Wnt Signaling Pathway | |||
| 5 | Wnt Signaling Pathway and Pluripotency | |||
| 6 | Wnt Signaling Pathway Netpath | |||
| 7 | Focal Adhesion | |||
| 8 | Extracellular vesicle-mediated signaling in recipient cells | |||
| 9 | Ectoderm Differentiation | |||
| 10 | Endoderm Differentiation | |||
| 11 | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| 12 | Hair Follicle Development: Organogenesis (Part 2 of 3) | |||
| 13 | Hair Follicle Development: Induction (Part 1 of 3) | |||
| 14 | Cytosolic sensors of pathogen-associated DNA | |||
| 15 | Primary Focal Segmental Glomerulosclerosis FSGS | |||
| 16 | BDNF signaling pathway | |||
| 17 | Integrated Pancreatic Cancer Pathway | |||
| 18 | Gastric cancer network 2 | |||
| 19 | Adipogenesis | |||
| 20 | Corticotropin-releasing hormone | |||
| 21 | Pathogenic Escherichia coli infection | |||
| 22 | Arrhythmogenic Right Ventricular Cardiomyopathy | |||
| 23 | Neural Crest Differentiation | |||
| 24 | TWEAK Signaling Pathway | |||
| 25 | miR-targeted genes in muscle cell - TarBase | |||
| 26 | miR-targeted genes in lymphocytes - TarBase | |||
| 27 | miR-targeted genes in leukocytes - TarBase | |||
| 28 | Integrated Breast Cancer Pathway | |||
| 29 | Myogenesis | |||
| 30 | Heart Development | |||
| 31 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 32 | Androgen receptor signaling pathway | |||
